Andrès E, Courouau F, Kurtz J E, Limacher J M, Quoix E
Service de pneumologie, CHU de Strasbourg.
Rev Pneumol Clin. 1995;51(4):228-31.
Pulmonary invasive aspergillosis is a frequent and poor prognosis complication of immunodeficiency and prolonged neutropenia. Its treatment is usually based on amphotericin given as intravenous infusion at 1 to 1.25 mg/kg/d. Use of lipid carriers give the opportunity to administrated higher dose, 5 mg/kg/d, with respect of renal function and good results in the primarily study. Intraconazole is now a good therapy after amphotericin, in the second time of disease.
